Vercirnon for the treatment of Crohn's disease

Expert Opinion on Investigational Drugs

Volumn 22, Issue 7, 2013, Pages 907-913

  Arseneau, Kristen O ^a   Cominelli, Fabio ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antagonism; CCL25; CCR9; CCX282 B; Chemokines; Crohn's disease; Inflammatory bowel disease; Thymus expressed chemokine; Traficet EN; Vercirnon

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; CHEMOKINE RECEPTOR CCR9; INFLIXIMAB; NATALIZUMAB; PLACEBO; SECUKINUMAB; USTEKINUMAB; VEDOLIZUMAB; VERCIRNON;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ARTHRALGIA; COMPETITIVE INHIBITION; CROHN DISEASE; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DYSPEPSIA; FEVER; GASTROINTESTINAL DISEASE; GENE DELETION; HEADACHE; HUMAN; ILEITIS; IMMUNE DEFICIENCY; MAINTENANCE THERAPY; NAUSEA; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; CROHN DISEASE; HUMANS; INTESTINAL MUCOSA; MOLECULAR STRUCTURE; RECEPTORS, CCR; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84879079378     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.795946     Document Type: Review

References (47)

1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126(6):1504-17
2. Tung J, Loftus EV Jr, Freese DK, et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2006;12(12):1093-100
3. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340(18):1398-405
4. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337(15):1029-35
5. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130(2):323-33
6. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132(1):52-65
7. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357(3):228-38
8. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357(3):239-50
9. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129(3):807-18
10. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007;146(12):829-38
11. Shao LM, Chen MY, Cai JT. Metaanalysis: the efficacy and safety of certolizumab pegol in Crohn's disease. Aliment Pharmacol Ther 2009;29(6):605-14
12. Guagnozz D, Caprilli R. Natalizumab in the treatment of Crohn's disease. Biologics 2008;2(2):275-84
13. Sandborn WJ, Colombel JF, Enns R, et al. Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353(18):1912-25
14. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132(5):1672-83
15. Baker DE. Natalizumab: overview of its pharmacology and safety. Rev Gastroenterol Disord 2007;7(1):38-46
16. McLean LP, Shea-Donohue T, Cross RK. Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. Immunotherapy 2012;4(9):883-98
17. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012;367(16):1519-28
18. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012;61(12):1693-700
19. Papadakis KA, Prehn J, Nelson V, et al. The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol 2000;165(9):5069-76
20. Linton L, Karlsson M, Grundstrom J, et al. HLA-DRhi and CCR9 define a pro-inflammatory monocyte subset in IBD. Clin Transl Gastroenterol 2012;e29, doi: 10.1038/ctg.2012.23 ase.
21. Zaballos A, Gutierrez J, Varona R, et al. Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. J Immunol 1999;162(10):5671-5
22. Kunkel EJ, Campbell JJ, Haraldsen G, et al. Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med 2000;192(5):761-8
23. Hieshima K, Kawasaki Y, Hanamoto H, et al. CC chemokine ligands 25 and 28 play essential roles in intestinal extravasation of IgA antibody-secreting cells. J Immunol 2004;173(6):3668-75
24. Papadakis KA, Landers C, Prehn J, et al. CC chemokine receptor 9 expression defines a subset of peripheral blood lymphocytes with mucosal T cell phenotype and Th1 or T-regulatory 1 cytokine profile. J Immunol 2003;171(1):159-65
25. Svensson M, Marsal J, Ericsson A, et al. CCL25 mediates the localization of recently activated CD8alphabeta(+) lymphocytes to the small-intestinal mucosa. J Clin Invest 2002;110(8):1113-21
26. Hosoe N, Miura S, Watanabe C, et al. Demonstration of functional role of TECK/CCL25 in T lymphocyte-endothelium interaction in inflamed and uninflamed intestinal mucosa. Am J Physiol Gastrointest Liver Physiol 2004;286(3):G458-66
27. Dudda JC, Lembo A, Bachtanian E, et al. Dendritic cells govern induction and reprogramming of polarized tissue-selective homing receptor patterns of T cells: important roles for soluble factors and tissue microenvironments. Eur J Immunol 2005;35(4):1056-65
28. Johansson-Lindbom B, Svensson M, Wurbel MA, et al. Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. J Exp Med 2003;198(6):963-9
29. Mora JR, Bono MR, Manjunath N, et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 2003;424(6944):88-93
30. Johansson-Lindbom B, Svensson M, Pabst O, et al. Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med 2005;202(8):1063-73
31. Annacker O, Coombes JL, Malmstrom V, et al. Essential role for CD103 in the T cell-mediated regulation of experimental colitis. J Exp Med 2005;202(8):1051-61
32. CSID:8518913. Available from: http://www.chemspider.com/Chemical- Structure.8518913.html [Accessed 18:59, Apr 4, 2013]
33. Walters MJ, Wang Y, Lai N, et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharm Exper Ther 2010;335:65-9
34. Yu CR, Peden KW, Zaitseva MB, et al. CCR9A and CCR9B: two receptors for the chemokine related CCL25/TECK/Ck beta-15 that differ in their sensitivities to ligand. J Immunol 2000;164(3):1293-305
35. Gosling J, Dairaghi DJ, Wang Y, et al. Cutting edge: identification of a novel chemokine receptor that binds dendritic cell-and T cell-active chemokines including ELC, SLC, and TECK. J Immunol 2000;164(6):2851-6
36. Kosiewicz MM, Nast CC, Krishnan A, et al. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. J Clin Invest 2001;107(6):695-702
37. Rivera-Nieves J, Bamias G, Vidrich A, et al. Emergence of perianal fistulizing disease in the SAMP1/YitFc mouse, a spontaneous model of chronic ileitis. Gastroenterology 2003;124(4):972-82
38. Rivera-Nieves J, Ho J, Bamias G, et al. Antibody blockade of CCL25/CCR9 ameliorates early but not late chronic murine ileitis. Gastroenterology 2006;131(5):1518-29
39. Kontoyiannis D, Pasparakis M, Pizarro TT, et al. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999;10(3):387-98
40. Bekker P, Keshav S, Johnson D, Schall TJ. PROTECT-1. Maintenance phase study results demonstrate efficacy of the intestine-specific chemokine receptor antagonist CCX282-B (Traficet-EN) in Crohn's disease. Inflamm Bowel Dis 1999;15:S11
41. Keshav S, Van?ásek T, Niv Y, et al. PROTECT-1 study of intestine-specific chemokine receptor antagonist CCX282-B (Traficet-EN) in Crohn's disease. Gut 2009;58:A468
42. Apostolaki M, Manoloukos M, Roulis M, et al. Role of b7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease. Gastroenterology 2008;134:2025-35
43. Wermers JD, McNamee EN, Wurbel MA, et al. The chemokine receptor CCR9 is required for the T-cell-mediated regulation of chronic ileitis in mice. Gastroenterology 2011;140(5):1526-35
44. Keshav S, Vanásek T, Niv Y, et al. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9 for patients with Crohn's diseases. PLoS One 2013; In press
45. Walters MJ, Ebsworth K, Sullivan TJ, et al. CCR9 inhibition does not interfere with the development of immune tolerance to oral antigens. Immunol Letters 2013; In press
46. Mann ER, McCarthy NE, Peake STC, et al. Skin-and gut-homing molecules on human circulating gd T cells and their dysregulation in inflammatory bowel disease. Clin Exper Immunol 2012;170(2):122-30
47. In the Crohn's Disease Drug Market, Total Sales of Remicade and Humira Will Begin to Decline in 2017 due in Part to the Increasing Uptake of Biosimilar Versions of These TNF-Alpha Inhibitors. Decision Resources Press Release. Decision Resources Group Co., Burlington, MA; 2012. Available from: http://decisionresources.com/News-and-Events/Press-Releases/Crohns-Disease- 092612